Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ICON Bioscience Inc

Criteria

Inclusion Criteria:

• Patients scheduled for unilateral cataract surgery

Exclusion Criteria:

• Ocular, topical, or oral corticosteroids within 7 days of Day 0